Episode
Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- Podcast
- Breast Cancer Update
- Published
- Jul 8, 2026
- Duration seconds
- 7200
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/antibody-drug-conjugates-in-the-management-of-breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/breast-cancer-update-757579/antibody-drug-conjugates-in-the-management-of-breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics: Introduction (00:00) Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57) Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01) Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36) Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36) Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10) CME information and select publications